Aims & Scope
The Journal of Alzheimers Disease is a peer-reviewed, open-access journal from Directive Publications dedicated to the science, diagnosis, treatment, and care of Alzheimer's disease and related neurodegenerative disorders. As a dedicated Alzheimer's disease journal, it serves neurologists, geriatricians, neuroscientists, neuropsychologists, gerontologists, and care researchers seeking a rigorous, internationally discoverable venue for original scholarship on dementia and cognitive decline.
The journal welcomes work across the full translational spectrum: amyloid-beta and tau biomarkers, neuroimaging, mild cognitive impairment, Lewy body dementia, vascular and frontotemporal dementia, and Parkinson's disease and parkinsonism. We particularly encourage studies on neuroprotection, non-pharmacological and e-health interventions, assistive technologies, activities of daily living, and quality of life and well-being for patients and caregivers.
We publish original research, systematic and narrative reviews, clinical case reports, methodological papers, and editorials. Every submission undergoes double-blind peer review; accepted articles appear open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright.
Each article receives a permanent Crossref DOI and is discoverable through OpenAlex, Google Scholar, and our OAI-PMH endpoint. The journal follows COPE ethical principles, and article-processing charges apply on acceptance with waivers and discounts available.
Subject Coverage
The Journal of Alzheimer's Disease welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in The Journal of Alzheimer's Disease — explore related research across our journals.
Articles
Mice With Scopolamine Induced Memory Impairment Carissa edulis Forssks Neuroprotective
Intrathecal Administration of Melatonin via Implanted Pump for the Management of Neurodegenerative
Further Analysis of a Cross Sectional Study on Factors Associated with Quality of Life in Patients
An All Inclusive Model of Variables Linked to Subjective Views of Living Well With Alzheimer
Frequently Asked Questions
What topics does The Journal of Alzheimers Disease cover?
The journal covers Alzheimer's disease and the broader spectrum of neurodegenerative and dementia research, including amyloid and tau biomarkers, mild cognitive impairment, Lewy body dementia, vascular and frontotemporal dementia, and Parkinson's disease and parkinsonism. It also welcomes studies on neuroprotection, non-pharmacological and e-health interventions, assistive technology, activities of daily living, and quality of life for patients and caregivers.
Who should read and publish in The Journal of Alzheimers Disease?
The journal is intended for neurologists, geriatricians, neuroscientists, neuropsychologists, gerontologists, dementia-care researchers, and clinical practitioners. Researchers studying any aspect of Alzheimer's disease, dementia, or neurodegeneration, from basic mechanisms to clinical care and quality of life, are encouraged to submit.
How do I submit a manuscript to The Journal of Alzheimers Disease?
Visit the journal's Submit page and follow the author guidelines for formatting and ethics requirements. Submissions are accepted year-round and enter double-blind peer review. The journal welcomes original research, reviews, clinical case reports, methodological papers, and editorials in Alzheimer's and neurodegenerative disease.
Is The Journal of Alzheimers Disease open access, and who holds copyright?
Yes. All accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, and authors retain copyright. This means readers worldwide can freely access, read, and cite Alzheimer's and dementia research published in the journal.
What type of peer review does the journal use and does every article get a DOI?
The journal uses double-blind peer review, in which author and reviewer identities are concealed from each other. Every accepted article is assigned a permanent Crossref DOI and is discoverable via OpenAlex, Google Scholar, and the journal's OAI-PMH endpoint for long-term citability.
Are there article-processing charges or fee waivers?
An article-processing charge applies on acceptance to sustain open-access publication, editorial handling, and permanent archiving. Waivers and discounts are available; authors who need fee support, including those from lower-income settings, are encouraged to request a waiver during submission.
What article types does The Journal of Alzheimers Disease accept?
The journal accepts original research articles, systematic and narrative reviews, clinical and translational case reports, short communications, methodological papers, and editorials addressing Alzheimer's disease, dementia subtypes, Parkinson's disease, neuroprotection, and patient care and quality of life.
Is the journal indexed in PubMed or Scopus?
As a new open-access publication, the journal is discoverable through Crossref DOIs, OpenAlex, Google Scholar, and its OAI-PMH endpoint, and it follows COPE ethical principles. It is building its publication record toward eligibility for services such as DOAJ and PubMed Central; it does not yet claim indexing in PubMed, Scopus, or Web of Science.